

iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
May 11, 2023
World-leading experts in CAR-T therapy discuss updates on CAR-T therapy in lymphoma, including efficacy, durability of response, and real-world experience. They also discuss the potential role of bispecific antibodies, challenges related to patient access and manufacturing, and potential strategies in treating CAR-T therapy resistance.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
CAR-T Therapy in Lymphoma and the Role of Bispecific Antibodies
02:25 • 3min
Exploring CAR-T Therapy in Lymphoma and the Role of Bispecific Antibodies
05:37 • 3min
CAR-T Therapy and Bispecific Antibodies in Lymphoma Treatment
08:34 • 4min
Challenges in CAR-T therapy resistance and the role of bispecific antibodies
12:43 • 3min